Eyebiotech Ltd.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 960
- Registration Number
- NCT06957080
- Locations
- 🇺🇸
Scottsdale, AZ, Scottsdale, Arizona, United States
🇺🇸Fayetteville, AR, Fayetteville, Arkansas, United States
🇺🇸Bakersfield, CA, Bakersfield, California, United States
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
- Conditions
- Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (NVAMD)BRVO - Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT06664502
- Locations
- 🇺🇸
Lemont, IL, Lemont, Illinois, United States
🇺🇸Asheville, NC, Asheville, North Carolina, United States
🇺🇸Wake Forest, NC, Wake Forest, North Carolina, United States
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 960
- Registration Number
- NCT06571045
- Locations
- 🇺🇸
Scottsdale, Scottsdale, Arizona, United States
🇺🇸Fayetteville, Arkansas, Fayetteville, Arkansas, United States
🇺🇸Springdale, Arkansas, Springdale, Arkansas, United States
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
- Conditions
- Neovascular Age-related Macular Degeneration (NVAMD)Diabetic Macular Edema (DME)
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05919693
- Locations
- 🇺🇸
Phoenix, AZ, Phoenix, Arizona, United States
🇺🇸Bakersfield, CA, Bakersfield, California, United States
🇺🇸Modesto, CA, Modesto, California, United States